Utility of the global CDR<sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium

2020159 citationsJournal Articlegreen Open Access

Authors

Toji Miyagawa · Mayo Clinic

Danielle Brushaber · Mayo Clinic

Jeremy A. Syrjanen · Mayo Clinic

Walter K. Kremers · Mayo Clinic

Julie A. Fields · Mayo Clinic

Leah K. Forsberg · Mayo Clinic

Hilary W. Heuer · University of California, San Francisco

Abstract

The global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.

Topics & Keywords

Neurobiology of Language and Bilingualism Dementia and Cognitive Impairment Research Parkinson's Disease Mechanisms and Treatments

Publication Details

Published in: Alzheimer s & Dementia

Volume 16, Issue 1, pp. 106-117

DOI: 10.1002/alz.12033

Field-Weighted Citation Impact: 9.45

Command Palette

Utility of the global CDR<sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium

Authors

Abstract

Topics & Keywords

Publication Details